Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene Symbol DDR2
Synonyms MIG20a | NTRKR3 | TKT | TYRO10 | WRCN
Gene Description DDR2, discoidin domain receptor tyrosine kinase 2, is a tyrosine kinase receptor activated by collagen, promoting cell migration, proliferation, and survival (PMID: 22328973, PMID: 27398168). Altered expression and mutations of DDR2 have been identified in a variety of solid tumors, including ovarian (PMID: 27398168), lung (PMID: 28161936), gastric (PMID: 27350126), and HNSCC (PMID: 27434411).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 act mut lung non-small cell carcinoma sensitive Lucitanib Preclinical Actionable In a preclinical study, Lucitanib (E-3810) decreased DDR2 phosphorylation, and inhibited proliferation and induced apoptosis in lung squamous cell carcinoma cells harboring a DDR2 activating mutation in culture (PMID: 24696502). 24696502
EML4 - ALK DDR2 amp lung non-small cell carcinoma predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, DDR2 amplification (PMID: 29636358). 29636358
DDR2 G253C Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G253C in culture (PMID: 22328973). 22328973
DDR2 G253C Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 G253C in culture (PMID: 22328973). 22328973
DDR2 G253C Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 G253C in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 G505S Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G505S in culture (PMID: 22328973). 22328973
DDR2 G505S Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 G505S in culture (PMID: 22328973). 22328973
DDR2 G505S Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 G505S in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 G774V Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G774V in culture (PMID: 22328973). 22328973
DDR2 G774V Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 G774V in culture (PMID: 22328973). 22328973
DDR2 G774V Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 G774V in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 I638F DDR2 T654M lung squamous cell carcinoma decreased response Dasatinib Preclinical Actionable In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 I638F resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
DDR2 I638F lung squamous cell carcinoma sensitive Dasatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell carcinoma cell line harboring a DDR2 I638F mutation in culture and in xenograft models (PMID: 22328973). 22328973
DDR2 I638F lung squamous cell carcinoma sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 I638F mutation in cell culture (PMID: 22328973). 22328973
DDR2 I638F Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973). 22328973
DDR2 I638F Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973). 22328973
DDR2 I638F Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 I638F in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 L239R lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 L239R mutation in culture (PMID: 22328973). 22328973
DDR2 L239R lung squamous cell carcinoma sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells harboring DDR2 L239R in culture (PMID: 22328973). 22328973
DDR2 L239R Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973). 22328973
DDR2 L239R Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973). 22328973
DDR2 L239R Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 L239R in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 L239R DDR2 T654M lung squamous cell carcinoma decreased response Dasatinib Preclinical Actionable In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 L239R resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
DDR2 L239R DDR2 T654I lung squamous cell carcinoma predicted - resistant Dasatinib Preclinical - Cell culture Actionable In a preclinical study, DDR2 T654I was identified as an acquired mutation in lung squamous cell carcinoma cells harboring DDR2 L239R that became resistant to Sprycel (dasatinib) in culture (PMID: 24296828). 24296828
DDR2 L63V lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) prevented colony formation and induced cell death in lung squamous cell carcinoma cells expressing DDR2 L63V in culture (PMID: 22328973). 22328973
DDR2 L63V Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973). 22328973
DDR2 L63V Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973). 22328973
DDR2 L63V Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) with Tasigna (nilotinib) reduced Src and Stat5 activation and inhibited proliferation of transformed cells expressing DDR2 L63V in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 mutant lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, lung squamous cell cancer cells harboring DDR2 mutations demonstrated sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
DDR2 over exp head and neck squamous cell carcinoma sensitive Dasatinib Preclinical - Cell culture Actionable In a preclinical study, Sprycel (dasatinib) inhibited cell migration and invasion of head and neck squamous cell carcinoma cells overexpressing Ddr2, in culture (PMID: 27434411). 27434411
DDR2 S768R lung squamous cell carcinoma predicted - sensitive Dasatinib Case Reports/Case Series Actionable In a clinical case study, patient with lung squamous cell carcinoma harboring a DDR2 S768R mutation had a positive response to (Sprycel) dasatinib treatment (PMID: 23932362). 23932362
DDR2 S768R lung squamous cell carcinoma predicted - sensitive Dasatinib + Erlotinib Case Reports/Case Series Actionable In a clinical case study, a squamous cell lung cancer patient that demonstrated a radiographic response following Sprycel (dasatinib) and Tarceva (erlotinib) combination treatment was found to carry a DDR2 S768R mutation (PMID: 22328973). 22328973